Loading…
Loading…
Sentiment · FY2026 Q1
| Analyst | Firm | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Jim Bhullar | JPMorgan | 13 | 31% |
| Andy Kligerman | TD Cowen | 13 | 15% |
| Jack Matten | BMO Capital Markets | 12 | 17% |
| Wes Carmichael | Wells Fargo | 11 | 18% |
| Wilma Burdis | Raymond James | 11 | 9% |
| John Barnidge | Piper Sandler | 9 | 0% |
| Elyse Greenspan | Wells Fargo | 9 | 0% |
| Suneet Kamath | Jefferies | 9 | 11% |
| Tom Gallagher | Evercore ISI | 8 | 13% |
| Ryan Krueger | KBW | 5 | 20% |
| Firm | Analysts | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Wells Fargo | 2 | 20 | 10% |
| JPMorgan | 2 | 15 | 27% |
| TD Cowen | 1 | 13 | 15% |
| BMO Capital Markets | 1 |
| 12 |
| 17% |
| Raymond James | 1 | 11 | 9% |
| Jefferies | 1 | 9 | 11% |
| Piper Sandler | 1 | 9 | 0% |
| Evercore ISI | 1 | 8 | 13% |
Revenue grew 5.4% with operating EPS of $3.43, up 12%, as Globe Life articulated an AI strategy for enterprise-wide margin expansion. United American Medicare Supplement sales continued explosive growth, and mortality trends sustained the earnings improvement trajectory. Management raised FY2026 guidance from $14.95-$15.65 to $15.40-$15.90, driven by accelerated buybacks and refined Q3 assumption update estimates.
Demand | Margin | Capital Allocation | Innovation & R&D | Regulation Policy | Competitive Dynamics | Guidance Reliability | Pricing | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 5 | 4 | 8 | 1 | 3 | 1 | 1 | |
| 2025Q1 | 4 | 6 | 5 | 1 | 2 | 1 | 4 | |
| 2025Q2 | 12 | 6 | 9 | 4 | 2 | 3 | 3 | 1 |
| 2025Q3 | 9 | 6 | 5 | 2 | 2 | 3 | 5 | |
| 2025Q4 | 8 | 5 | 3 | 1 | 1 | 2 | 1 | 1 |
| 2026Q1 | 6 | 8 | 3 | 3 | 1 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 5 | 4 | 12 | 9 | 8 | 6 |
| Margin | 4 | 6 | 6 | 6 | 5 | 8 |
| Capital Allocation | 8 | 5 | 9 | 5 | 3 | 3 |
| Innovation & R&D | 1 | 1 | 4 | 2 | 1 | 3 |
| Regulation Policy | 3 | 2 | 2 | 2 | 1 | 1 |
| Competitive Dynamics | 1 | 3 | 3 | 2 | 1 | |
| Guidance Reliability | 1 | 3 | 5 | 1 | ||
| Pricing | 1 | 4 | 1 | 1 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
GL Globe Life | 8 | +5.3% | |
| AFL Aflac | 6 | +25.0% | |
| MET MetLife | 7 | +4.4% | |
| PRU Prudential Financial | 7 | +6.3% |